Please read the following statements carefully.

Your healthcare provider has prescribed REVLIMID for your child.* REVLIMID is available only through a restricted distribution program called the REVLIMID Risk Evaluation and Mitigation Strategy (REMS). Before taking REVLIMID, patients must read and agree to all of the instructions in the REVLIMID REMS® program. Any unborn baby of a girl taking REVLIMID can have severe birth defects or even die.

REVLIMID causes low white blood cells (neutropenia) and low platelets (thrombocytopenia) in most patients.

REVLIMID causes a higher chance for blood clots in your arteries (heart attacks and strokes), veins (deep vein thrombosis) and lungs (pulmonary embolism). To reduce this increased risk, most people who take REVLIMID will also take a blood thinner medicine.

For more information, please see the REVLIMID Medication Guide.

INSTRUCTIONS

Before your child starts treatment with REVLIMID, you will need to:
1. Complete sections 1 and 2 of this form and sign and date on page 5.
2. Read the REVLIMID REMS® materials contained in the Patient Resource Pack.
3. Keep a copy of this form for your records.

For more information, visit www.CelgeneRiskManagement.com, or call the Celgene Customer Care Center at 1-888-423-5436.

*Throughout this form, the word child includes any child of whom you are the parent or guardian.
Please read the following statements carefully. Mark the box (with an “X”) if you agree with the statement. Please do not mark or write outside of designated areas.

Section 1. Patient Agreement

I understand and confirm that:

☐ REVIMLID can cause severe birth defects or death to unborn babies of females taking REVIMLID
☐ My child is not pregnant
☐ My child is not able to get pregnant because she has not yet started her period (is not menstruating)
☐ My child’s REVIMLID prescription is only for her and is not to be shared with others
☐ We have read and understood the REVIMLID Patient Guide to the REVIMLID REMS® Program and/or educational materials, including the Medication Guide. These materials include information about the possible health problems and side effects that REVIMLID may cause
☐ My child’s healthcare provider has reviewed this information with us and answered any questions we have asked
☐ We may be contacted by Celgene to assist with the REVIMLID REMS® program
REVLIMID® (lenalidomide) Patient-Physician Agreement Form

Female Child Who Can Not Get Pregnant

I will tell my child that:

☐ We will complete the mandatory confidential monthly survey while my child is taking REVLIMID
☐ We will keep my child’s REVLIMID prescription out of the reach of other children
☐ We will return any unused REVLIMID capsules for disposal to Celgene by calling 1-888-423-5436. Celgene will pay for the shipping costs. I understand that Celgene cannot give me a refund for the capsules my child did not take. Unused REVLIMID capsules can also be returned to my child’s REVLIMID prescriber, or to the pharmacy that dispensed the REVLIMID to my child
☐ She must not share REVLIMID capsules with anyone even if they have symptoms like hers
☐ She must not donate blood while taking REVLIMID (including dose interruptions) and for 4 weeks after stopping REVLIMID

For Example Purposes Only: Call 1-888-423-5436 for patient enrollment information.
Section 2. Authorization

I understand and confirm that:

☐ By signing this authorization, I allow my child’s healthcare providers and pharmacies to share my child’s medical and other health information with Celgene Corporation and other companies that Celgene works with to:
  • Coordinate the delivery of products and services available from pharmacies and Celgene patient assistance programs, including Celgene Patient Support®, and other companies
  • Analyze data for internal business purposes on the use of REVLIMID
  • Evaluate the effectiveness of the REVLIMID REMS® program
  • Use in any other manner as required or permitted by law
  • Provide me and my child with information about REVLIMID or my child’s condition

☐ This authorization will remain in effect for 12 months after my child stops REVLIMID. However, it may be revoked (cancelled) earlier by me, at any time, once I inform my child’s healthcare provider that my child will no longer be a part of the REVLIMID REMS® program

☐ Once my child’s information is shared as noted above, and to process and coordinate the delivery of product, there is no guarantee that the person receiving the information will not share it with another party

☐ I may refuse to sign this authorization, which means that I do not want my child to participate in the REVLIMID REMS® program. I understand that by refusing to have my child participate in the REVLIMID REMS® program, she will not be able to receive REVLIMID. However, I understand that I can speak with my child’s healthcare provider about other treatment options for my child’s condition

☐ Upon signing this form, I authorize my child’s healthcare provider to begin my child’s treatment with REVLIMID
Female Child Who Can Not Get Pregnant

Section 3. Authorization to Start Treatment

I have read the information on this form or it has been read aloud to me in the language of my choice. I understand that if my child does not follow all of the instructions regarding the REVLIMID REMS® program, she will not be able to receive REVLIMID. I also understand that the information we provide on this form and as part of the surveys we will complete during treatment will be known by the manufacturer of REVLIMID and the Food and Drug Administration (FDA).

I agree that the prescriber has fully explained to the patient and her parent/guardian the nature, purpose, and risks of the treatment described above, especially the potential risks to females who can get pregnant. The prescriber has asked the patient and her parent/guardian if they have any questions regarding the child’s treatment with REVLIMID and has answered those questions to the patient’s, parent/guardian’s, and prescriber’s mutual satisfaction. The patient, parent/guardian, and prescriber certify that they will comply with all of their obligations and responsibilities as described under the REVLIMID REMS® program.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Prescriber</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Name</td>
</tr>
<tr>
<td>Identification Number</td>
<td>Identification Number</td>
</tr>
<tr>
<td>Address</td>
<td>Address</td>
</tr>
<tr>
<td>Telephone Number</td>
<td>Telephone Number</td>
</tr>
<tr>
<td>Date of Birth</td>
<td>Sex</td>
</tr>
<tr>
<td>Risk Category</td>
<td>Fax Number</td>
</tr>
<tr>
<td>Menstruating:</td>
<td></td>
</tr>
<tr>
<td>Surgical Menopause:</td>
<td></td>
</tr>
<tr>
<td>Natural Menopause (24 months):</td>
<td></td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
</tr>
</tbody>
</table>

Patient or Authorized Representative’s Signature:  
Prescriber’s Signature:

Signature Date:  
Signature Date:

Prescriber, please fax all pages of the completed form to 1-888-432-9325.
Give a copy of the form to the parent/guardian.

BAR CODE HERE

For Example Purposes Only: Call 1-888-423-5436 for patient enrollment information.